State corporation Rostec, Rusnano group and the pharmaceutical company Ishvan Pharmaceuticals will build a major production complex in Russia’s Kaluga Region to produce live and inactivated vaccines. It is expected that by 2025 the production capacity of the new enterprise will reach 4 million doses per year.
”The Russian pharmaceutical market has always been a top priority for us. Cooperation with State Corporation Rostec and the Rusnano Group opens great opportunities. Implementation of innovations by means of localization of production and transfer of technologies from our partners such as the Serum Institute of India and Zydus Cadila using mRNA technology should position the created products to quickly take the leading positions in the market,” said CEO of Ishvan Pharmaceuticals Debadutta Mishra.
Employing the services of the pharmaceutical company Pharm Aid Ltd., the parties aim to create a modern production facility in the Kaluga region to produce vaccines that will prevent the rotavirus infection, chickenpox, and human papillomavirus. In the future, they hope to fight other diseases as well. The enterprise will use the technological processes of the world's largest vaccine manufacturer, Serum Institute of India, while being fully located in Russia.
State Corporation Rostec will be involved in the implementation of large-scale infrastructure projects during the building of the production facility. They are also planning to leverage the intellectual potential of the Rusnano group and benefit from their substantial scientific expertise.
